- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07825077
Effects of AI Dialogue-Based Scenario Simulation on Students' Flow and Learning Performance
The Effects of Scenario Simulation Via AI Dialogue Integrated With Concept Mapping and Gamified Feedback on Students' Flow and Learning Performance: The Roles of Collaborative Processes and Interaction Mechanisms
This study examines the effects of an AI dialogue-based scenario simulation integrated with concept mapping and post-dialogue feedback on nursing students' learning. Nursing students will participate in pediatric care scenarios using standardized AI-supported dialogues. Two feedback approaches will be compared: gamified feedback and conventional formative feedback without gamification elements. The study will examine students' flow experience and learning performance and explore how collaborative processes and interaction mechanisms may contribute to these outcomes. The findings are expected to provide evidence on how different feedback approaches influence students' engagement and learning during AI-supported scenario simulation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bao Huan Yang, PhD
- Phone Number: +88632118999 ext 3401
- Email: bhyang@mail.cgust.edu.tw
Study Locations
-
-
Taoyuan City
-
Taoyuan, Taoyuan City, Taiwan, 333324
- Chang Gung University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Undergraduate nursing students enrolled in the designated nursing course during the study period.
- Aged 18 years or older.
- Willing to participate and providing informed consent.
Exclusion Criteria:
- Students who decline or do not provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Gamified Feedback Group
Participants receive a concept-mapping-integrated AI dialogue-based scenario simulation followed by gamified feedback. The feedback includes gamification elements such as points, levels, progress indicators, and mission-based features. |
Gamified feedback is delivered following the AI dialogue-based scenario simulation and includes game-related elements such as points, levels, progress indicators, and mission-based features. |
|
Active Comparator: Conventional Formative Feedback Group
Participants receive the same concept-mapping-integrated AI dialogue-based scenario simulation followed by conventional formative feedback without gamification elements. |
Conventional formative feedback is delivered following the same AI dialogue-based scenario simulation without gamification elements. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow Experience
Time Frame: Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).
|
Flow experience will be assessed using the 8-item Flow Experience Questionnaire developed by Pearce et al. (2005). Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate a greater level of flow experience. Descriptive statistics will be used to examine the distribution and change in flow scores, missing data, and internal consistency. |
Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).
|
|
Academic Learning Performance
Time Frame: At approximately Week 9 (midterm examination) and Week 18 (final examination) of the academic semester.
|
Academic learning performance will be assessed using students' course midterm and final examination scores. Higher scores indicate better academic performance. |
At approximately Week 9 (midterm examination) and Week 18 (final examination) of the academic semester.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intrinsic Motivation
Time Frame: Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).
|
Intrinsic motivation will be assessed using a 25-item version of the Intrinsic Motivation Inventory (IMI), based on the IMI framework of McAuley et al. (1989) and the version adapted by Yin et al. (2021). Items are rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). The instrument assesses five dimensions: interest/enjoyment, pressure/tension, perceived choice, perceived competence, and perceived value. Reverse-coded items will be recoded before analysis, and each subscale score will be calculated as the mean of its constituent items. |
Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB-26-058-B1
- NSTC 115-2410-H-255-014 (Other Grant/Funding Number: National Science and Technology Council)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.